Hopkinton-based biotech company Arteriocyte has a deal with the U.S. Army to investigate new stem cell therapies for use in treating soldiers wounded in battle.
The company has a three-year research and development agreement with the Army’s Institute of Surgical Research at Fort Sam Houston, Texas.
Arteriocyte will be testing two technologies, including its Magellan MAR01 system, which has FDA approval. The system allows for the rapid deployment of platelet-rich plasma from blood and bone marrow to help spur tissue repair in wounded patients.
The new agreement will enable Arterioctye to work with the Army’s staff at Fort Sam Houston on using Magellan to treat traumatic limb injuries.
